Inclusion Criteria:  Participant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and unfit for intensive chemotherapy Participant must be >= 60 years of age. Participant must have a projected life expectancy of at least 12 weeks. Participant must have adequate renal function as demonstrated by a creatinine >= 30 mL/min;determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula  Participant must have adequate liver function as demonstrated by:  aspartate aminotransferase (AST) <= 3.0 x ULN* alanine aminotransferase (ALT) <= 3.0 x ULN* bilirubin <= 1.5 x ULN* * Unless considered to be due to leukemic organ involvement i. Subjects who are < 75 years of age may have a bilirubin of <= 3.0 x ULN  Exclusion Criteria:  Participant has history of myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation Participant has acute promyelocytic leukemia Participant has known active central nervous system (CNS) involvement with AML Participant is known to be positive for hepatitis B or C infection Participant has received anticancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents within 5 half-lives prior to first dose of study drug Participant has received biologic agents (e.g. monoclonal antibodies) for anti-neoplastic intent within 30 days prior to first dose of study drug  Participant has received the following within 7 days prior to the first dose of the study drug:  Steroid therapy for anti-neoplastic intent; Strong and Moderate CYP3A inhibitors (see Appendix A for examples) Strong and Moderate CYP3A inducers (see Appendix A for examples) Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy Participant has a serious cardiovascular, pulmonary or renal disability  Participant has a history of other malignancies within 2 years prior to study entry, with the exception of:  Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; requires discussion with TA MD.